QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
NASDAQ:XENE

Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

$36.53
+0.51 (+1.42%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$35.64
▼
$37.36
50-Day Range
$33.06
▼
$38.89
52-Week Range
$24.36
▼
$41.39
Volume
340,521 shs
Average Volume
446,876 shs
Market Capitalization
$2.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.50

Xenon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
35.5% Upside
$49.50 Price Target
Short Interest
Bearish
5.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Xenon Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$138,005 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.13) to ($2.93) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

877th out of 1,022 stocks

Pharmaceutical Preparations Industry

428th out of 499 stocks

See Top Rated MarketRank™ Stocks Here
XENE stock logo

About Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Stock News Headlines

December 8, 2022 | americanbankingnews.com
Analysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) PT at $49.50
December 2, 2022 | finance.yahoo.com
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
December 8, 2022 | Investing Trends (Ad)
How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
December 2, 2022 | finance.yahoo.com
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
December 1, 2022 | americanbankingnews.com
Traders Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)
December 1, 2022 | americanbankingnews.com
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
November 30, 2022 | finance.yahoo.com
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
November 30, 2022 | finance.yahoo.com
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
December 8, 2022 | Investing Trends (Ad)
How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
November 30, 2022 | americanbankingnews.com
Insider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Sells 2,057 Shares of Stock
November 30, 2022 | americanbankingnews.com
Xenon Pharmaceuticals (NASDAQ:XENE) Research Coverage Started at Wells Fargo & Company
November 28, 2022 | markets.businessinsider.com
Where Xenon Pharmaceuticals Stands With Analysts
November 12, 2022 | finance.yahoo.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Analysts Just Trimmed Their Revenue Forecasts By 10%
November 8, 2022 | seekingalpha.com
Xenon Pharmaceuticals Inc. (XENE) Q3 2022 Earnings Call Transcript
November 8, 2022 | finance.yahoo.com
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
November 8, 2022 | msn.com
Earnings Preview: Xenon Pharmaceuticals
November 7, 2022 | finance.yahoo.com
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
November 3, 2022 | finance.yahoo.com
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
November 2, 2022 | apnews.com
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
November 1, 2022 | finance.yahoo.com
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
October 6, 2022 | finance.yahoo.com
Are Investors Undervaluing Xenon Pharmaceuticals Inc. (NASDAQ:XENE) By 32%?
October 6, 2022 | finance.yahoo.com
Xenon Pharmaceuticals Inc. (XENE)
September 21, 2022 | seekingalpha.com
XENE Xenon Pharmaceuticals Inc.
September 1, 2022 | finance.yahoo.com
Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
August 29, 2022 | finance.yahoo.com
10 Best Biotech Stocks To Buy Now
August 29, 2022 | markets.businessinsider.com
Analyst Ratings for Xenon Pharmaceuticals
August 18, 2022 | seekingalpha.com
Xenon Pharmaceuticals (XENE) Investor Presentation - Slideshow
See More Headlines
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Company Calendar

Last Earnings
11/10/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENE
CUSIP
N/A
CIK
1582313
Web
www.xenon-pharma.com
Phone
(604) 484-3300
Fax
604-484-3450
Employees
149
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.50
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+35.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-78,880,000.00
Net Margins
-862.06%
Pretax Margin
-866.14%
Return on Equity
-17.31%
Return on Assets
-16.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
41.78
Quick Ratio
41.78

Sales & Book Value

Annual Sales
$18.44 million
Price / Sales
123.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.51 per share
Price / Book
3.48

Miscellaneous

Outstanding Shares
62,544,000
Free Float
58,754,000
Market Cap
$2.28 billion
Optionable
Optionable
Beta
1.40

Key Executives

  • Mr. Ian C. Mortimer C.M.A. (Age 46)
    CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director
    Comp: $957.16k
  • Ms. Sherry Aulin (Age 38)
    Chief Financial Officer
    Comp: $458.64k
  • Dr. Christopher John Kenney M.D.Dr. Christopher John Kenney M.D. (Age 51)
    Chief Medical Officer
    Comp: $494.83k
  • Ms. Jodi Regts M.B.A.
    B.A., MBA, VP of Corp. Affairs & Investor Relations
  • Ms. Shelley McCloskey B.A. (Age 62)
    Exec. VP of HR
  • Dr. Robin P. Sherrington Ph.D. (Age 61)
    Exec. VP of Strategy & Innovation
  • Dr. James R. Empfield Ph.D. (Age 61)
    Exec. VP of Drug Discovery
  • Ms. Sheila M. Grant M.B.A.
    M.Sc., MBA, Exec. VP of R&D Operations
  • Dr. Christopher E. Von Seggern M.B.A. (Age 43)
    M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
  • Dr. Kenneth Sommerville
    Interim Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













XENE Stock - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price forecast for 2023?

9 Wall Street analysts have issued 12 month price objectives for Xenon Pharmaceuticals' shares. Their XENE share price forecasts range from $45.00 to $55.00. On average, they predict the company's stock price to reach $49.50 in the next year. This suggests a possible upside of 34.5% from the stock's current price.
View analysts price targets for XENE or view top-rated stocks among Wall Street analysts.

How have XENE shares performed in 2022?

Xenon Pharmaceuticals' stock was trading at $31.24 at the beginning of 2022. Since then, XENE stock has increased by 17.8% and is now trading at $36.80.
View the best growth stocks for 2022 here.

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our XENE earnings forecast.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.08. The biopharmaceutical company earned $8.12 million during the quarter, compared to the consensus estimate of $7.76 million. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 17.31% and a negative net margin of 862.06%. During the same quarter in the prior year, the company earned ($0.25) EPS.

What other stocks do shareholders of Xenon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Marshall Wace LLP (4.49%), Pictet Asset Management SA (3.66%), Lord Abbett & CO. LLC (3.06%), Point72 Asset Management L.P. (2.62%), Samlyn Capital LLC (2.06%) and BlackRock Inc. (1.67%). Insiders that own company stock include Christopher John Kenney, Frank A Holler, Gary Patou, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $36.80.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.30 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78,880,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

The company employs 149 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.

This page (NASDAQ:XENE) was last updated on 12/8/2022 by MarketBeat.com Staff